Skip to main content

Table 3 Example 2 Results. Predicted sojourn times and mortality for patients in data example from Grein et al. [9] at 28 days of follow-up. Start: time of treatment initiation, Non-MV: noninvasive positive pressure ventilation, nasal high-flow oxygen therapy, low-flow oxygen, and ambient air, MV: ECMO and MV (): 95% confidence interval for duration estimates, (): standard error for risk estimates

From: Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach

  53 patients with severe COVID-19 treated with Remdesivir (Grein et al.), results at day 28
Non-MV Duration in Days MV Duration in Days Total Length of ICU Stay in Days Death Risk
Start Non-MV 16.26 (13.87, 18.56) 1.41 (0.27, 2.96) 17.67 (14.14, 21.52) 6.2% (3.3)
Start MV 6.14 (3.86, 8.41) 14.57 (11.99, 17.31) 20.71 (15.85, 25.72) 19.8% (6.4)
Full Cohort 9.77 (7.76, 11.81) 9.85 (7.68, 12.14) 19.62 (15.44, 23.95) 15.0% (5.3)